TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Mobile Health Approach to Reducing Sedentary Time in Bariatric Surgery Patients
Brief Summary: Greater time spent in sedentary behaviors, independent of physical activity level, can increase risk of morbidity and mortality. Objective assessments indicate that bariatric surgery patients spend large amounts of time in sedentary behaviors. The present study is the first to test whether a mobile health (mHealth) approach that employs widely adopted smartphone technology to monitor and modify sedentary behaviors as they occur is a feasible and acceptable method of reducing sedentary time in these patients and other obese populations.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: text messages related to sedentary behaviour | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: text messages related to sedentary behaviour; Assigned to Arm(s): Intervention
B: Arm Label: Behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral intervention to reduce sedentary time delivered via mobile smartphone | Intervention Type: BEHAVIORAL; Name: Behavioral intervention to reduce sedentary time delivered via mobile smartphone; Assigned to Arm(s): Behavioral intervention
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Theoretical & practical exercise counseling | Intervention Type: BEHAVIORAL; Name: Theoretical & practical exercise counseling; Assigned to Arm(s): Exercise
D: Arm Label: High Volume; Type: ACTIVE_COMPARATOR; Interventions: Other: High Volume | Arm Label: Moderate Volume; Type: ACTIVE_COMPARATOR; Interventions: Other: Moderate Volume | Intervention Type: OTHER; Name: Moderate Volume; Assigned to Arm(s): Moderate Volume | Intervention Type: OTHER; Name: High Volume; Assigned to Arm(s): High Volume

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Time-differentiated Treatment With Mild Therapeutic Hypothermia Following Cardiac Arrest, a Multi Center Study.
Brief Summary: The purpose of this study is to determine if 48 hours of mild therapeutic hypothermia following out of hospital cardiac arrest gives a better cerebral outcome compared to 24 hours therapeutic hypothermia.


Options:
A: Arm Label: 24 hours hypothermia; Type: ACTIVE_COMPARATOR; Interventions: Other: Therapeutic hypothermia | Arm Label: 48 hours hypothermoa; Type: EXPERIMENTAL; Interventions: Other: Therapeutic hypothermia | Intervention Type: OTHER; Name: Therapeutic hypothermia; Assigned to Arm(s): 24 hours hypothermia, 48 hours hypothermoa
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hypothermia; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Mild therapeutic hypothermia | Intervention Type: PROCEDURE; Name: Mild therapeutic hypothermia; Assigned to Arm(s): Hypothermia
C: Arm Label: control treatment; Type: NO_INTERVENTION; Interventions: Other: Rapid infusion of 2 liters of 4oC normal saline, Drug: Rapid infusion of cold normal saline | Intervention Type: OTHER; Name: Rapid infusion of 2 liters of 4oC normal saline; Assigned to Arm(s): control treatment | Intervention Type: DRUG; Name: Rapid infusion of cold normal saline; Assigned to Arm(s): control treatment
D: Arm Label: Normothermia; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard care with early treatment of fever | Arm Label: Hypothermia; Type: EXPERIMENTAL; Interventions: Procedure: Targeted temperature management to 33°C | Intervention Type: PROCEDURE; Name: Targeted temperature management to 33°C; Assigned to Arm(s): Hypothermia | Intervention Type: PROCEDURE; Name: Standard care with early treatment of fever; Assigned to Arm(s): Normothermia

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Brief Summary: To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma, as measured by progression-free survival (PFS), assessed by the study site investigator.


Options:
A: Arm Label: Imiquimod; Type: EXPERIMENTAL; Interventions: Drug: Imiquimod cream + surgery | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + surgery | Intervention Type: DRUG; Name: Imiquimod cream + surgery; Assigned to Arm(s): Imiquimod | Intervention Type: DRUG; Name: Placebo + surgery; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody, Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody | Intervention Type: DRUG; Name: MDX-010 (anti-CTLA4) monoclonal antibody; Assigned to Arm(s): 2, 3 | Intervention Type: BIOLOGICAL; Name: MDX-1379 (gp100) Melanoma Peptide Vaccine; Assigned to Arm(s): 1, 2
C: Arm Label: GSK2118436; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Arm Label: Dacarbazine (DTIC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine (DTIC) | Arm Label: Crossover; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Intervention Type: DRUG; Name: GSK2118436; Assigned to Arm(s): Crossover, GSK2118436 | Intervention Type: DRUG; Name: Dacarbazine (DTIC); Assigned to Arm(s): Dacarbazine (DTIC)
D: Arm Label: Placebo + Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Vemurafenib | Arm Label: Cobimetinib + Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Vemurafenib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Cobimetinib + Vemurafenib, Placebo + Vemurafenib | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Cobimetinib + Vemurafenib

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Brief Summary: To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma, as measured by progression-free survival (PFS), assessed by the study site investigator.


Options:
A: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: pembrolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: pembrolizumab; Assigned to Arm(s): Pembrolizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
C: Arm Label: Ipilimumab and Placebo matching Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Other: Placebo matching Nivolumab | Arm Label: Nivolumab and Placebo matching Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Other: Placebo matching Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Ipilimumab and Placebo matching Nivolumab | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab and Placebo matching Ipilimumab | Intervention Type: OTHER; Name: Placebo matching Ipilimumab; Assigned to Arm(s): Nivolumab and Placebo matching Ipilimumab | Intervention Type: OTHER; Name: Placebo matching Nivolumab; Assigned to Arm(s): Ipilimumab and Placebo matching Nivolumab
D: Arm Label: Placebo + Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Vemurafenib | Arm Label: Cobimetinib + Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Vemurafenib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Cobimetinib + Vemurafenib, Placebo + Vemurafenib | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Cobimetinib + Vemurafenib

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Brief Summary: To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma, as measured by progression-free survival (PFS), assessed by the study site investigator.


Options:
A: Arm Label: Placebo + Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Vemurafenib | Arm Label: Cobimetinib + Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Vemurafenib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Cobimetinib + Vemurafenib, Placebo + Vemurafenib | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Cobimetinib + Vemurafenib
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody, Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody | Intervention Type: DRUG; Name: MDX-010 (anti-CTLA4) monoclonal antibody; Assigned to Arm(s): 2, 3 | Intervention Type: BIOLOGICAL; Name: MDX-1379 (gp100) Melanoma Peptide Vaccine; Assigned to Arm(s): 1, 2
C: Arm Label: RCM-OSS procedure; Type: EXPERIMENTAL; Interventions: Device: Reflectance confocal microscopy, Procedure: Surgical excision | Arm Label: Standard of care procedure; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Punch biopsy, Procedure: Surgical excision | Intervention Type: DEVICE; Name: Reflectance confocal microscopy; Assigned to Arm(s): RCM-OSS procedure | Intervention Type: PROCEDURE; Name: Punch biopsy; Assigned to Arm(s): Standard of care procedure | Intervention Type: PROCEDURE; Name: Surgical excision; Assigned to Arm(s): RCM-OSS procedure, Standard of care procedure
D: Arm Label: Standard of care procedure; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Punch biopsy, Procedure: Surgical excision | Arm Label: Reflectance confocal microscopy (RCM); Type: EXPERIMENTAL; Interventions: Device: Reflectance confocal microscopy, Procedure: Surgical excision | Intervention Type: DEVICE; Name: Reflectance confocal microscopy; Assigned to Arm(s): Reflectance confocal microscopy (RCM) | Intervention Type: PROCEDURE; Name: Punch biopsy; Assigned to Arm(s): Standard of care procedure | Intervention Type: PROCEDURE; Name: Surgical excision; Assigned to Arm(s): Reflectance confocal microscopy (RCM), Standard of care procedure

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Brief Summary: To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma, as measured by progression-free survival (PFS), assessed by the study site investigator.


Options:
A: Arm Label: Arm A: Adjuvant Nivolumab (Complete Pathological Response); Type: ACTIVE_COMPARATOR; Interventions: Drug: nivolumab | Arm Label: Arm B: Adjuvant Nivolumab (Less than Complete Response); Type: ACTIVE_COMPARATOR; Interventions: Drug: nivolumab | Arm Label: Arm C: Adjuvant Combination (Less than Complete Response); Type: EXPERIMENTAL; Interventions: Drug: nivolumab, Drug: Ipilimumab | Intervention Type: DRUG; Name: nivolumab; Assigned to Arm(s): Arm A: Adjuvant Nivolumab (Complete Pathological Response), Arm B: Adjuvant Nivolumab (Less than Complete Response), Arm C: Adjuvant Combination (Less than Complete Response) | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Arm C: Adjuvant Combination (Less than Complete Response)
B: Arm Label: Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
C: Arm Label: Placebo + Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Vemurafenib | Arm Label: Cobimetinib + Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Vemurafenib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Cobimetinib + Vemurafenib, Placebo + Vemurafenib | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Cobimetinib + Vemurafenib
D: Intervention Type: BIOLOGICAL; Name: GM2-KLH vaccine; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: QS21; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Suicidal Ideation Through Insomnia Treatment
Brief Summary: Epidemiologic reports have linked insomnia to suicidal ideation and suicide death. However, no studies have determined whether treating insomnia decreases the risk of suicidality. We have new data indicating that (1) the link between insomnia and suicidal ideation holds true in clinical trials of depressed insomniacs, (2) dysfunctional cognitions about sleep are related to suicidal ideas, and (3) treatment of insomnia with hypnotics leads to a reduction of suicidal ideation. We now propose to test whether cautious use of hypnotics in suicidal, depressed insomniacs may reduce suicide risk in a multi-site clinical trial.


Options:
A: Arm Label: Zolpidem-CR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem-CR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zolpidem-CR; Assigned to Arm(s): Zolpidem-CR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Mindfulness skills; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness skills training | Arm Label: Interpersonal effectiveness skills; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interpersonal Effectiveness skills training | Intervention Type: BEHAVIORAL; Name: Mindfulness skills training; Assigned to Arm(s): Mindfulness skills | Intervention Type: BEHAVIORAL; Name: Interpersonal Effectiveness skills training; Assigned to Arm(s): Interpersonal effectiveness skills
C: Arm Label: Priovi; Type: EXPERIMENTAL; Interventions: Behavioral: Priovi, Other: CAU | Arm Label: Care-as-Usual (CAU) / wait list; Type: ACTIVE_COMPARATOR; Interventions: Other: CAU | Intervention Type: BEHAVIORAL; Name: Priovi; Assigned to Arm(s): Priovi | Intervention Type: OTHER; Name: CAU; Assigned to Arm(s): Care-as-Usual (CAU) / wait list, Priovi
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Active group; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): Active group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Suicidal Ideation Through Insomnia Treatment
Brief Summary: Epidemiologic reports have linked insomnia to suicidal ideation and suicide death. However, no studies have determined whether treating insomnia decreases the risk of suicidality. We have new data indicating that (1) the link between insomnia and suicidal ideation holds true in clinical trials of depressed insomniacs, (2) dysfunctional cognitions about sleep are related to suicidal ideas, and (3) treatment of insomnia with hypnotics leads to a reduction of suicidal ideation. We now propose to test whether cautious use of hypnotics in suicidal, depressed insomniacs may reduce suicide risk in a multi-site clinical trial.


Options:
A: Arm Label: Dialectical Behavior Therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Dialectical Behavior Therapy | Arm Label: Dialectical Behavior Therapy placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy | Arm Label: Supportive therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Supportive psychotherapy | Arm Label: Supportive therapy placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive psychotherapy | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Supportive therapy Fluoxetine | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Dialectical Behavior Therapy placebo | Intervention Type: BEHAVIORAL; Name: Supportive psychotherapy; Assigned to Arm(s): Supportive therapy Fluoxetine, Supportive therapy placebo
B: Arm Label: Youth culturally adapted therapy (Y-CMAP); Type: EXPERIMENTAL; Interventions: Behavioral: Youth Culturally Adapted Manual Assisted Psychological Therapy (Y-CMAP) | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Youth Culturally Adapted Manual Assisted Psychological Therapy (Y-CMAP); Assigned to Arm(s): Youth culturally adapted therapy (Y-CMAP)
C: Arm Label: Control (volitional help sheet); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Volitional help sheet | Arm Label: Intervention (volitional help sheet); Type: EXPERIMENTAL; Interventions: Behavioral: Volitional help sheet | Intervention Type: BEHAVIORAL; Name: Volitional help sheet; Assigned to Arm(s): Control (volitional help sheet) | Intervention Type: BEHAVIORAL; Name: Volitional help sheet; Assigned to Arm(s): Intervention (volitional help sheet)
D: Arm Label: Zolpidem-CR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem-CR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zolpidem-CR; Assigned to Arm(s): Zolpidem-CR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Brief Summary: This study will test the clinical effectiveness and safety of apremilast compared with placebo as well as etanercept compared with placebo in the same group of patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: Risankizumab; Type: EXPERIMENTAL; Interventions: Drug: Risankizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Risankizumab; Assigned to Arm(s): Risankizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: BI 695501; Type: EXPERIMENTAL; Interventions: Drug: BI 695501 | Arm Label: Humira; Type: ACTIVE_COMPARATOR; Interventions: Drug: Humira | Intervention Type: DRUG; Name: BI 695501; Assigned to Arm(s): BI 695501 | Intervention Type: DRUG; Name: Humira; Assigned to Arm(s): Humira
C: Arm Label: Adalimumab (Humira); Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab (Humira) | Arm Label: Placebo Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Injection | Arm Label: NB-UVB phototherapy; Type: ACTIVE_COMPARATOR; Interventions: Other: NB-UVB phototherapy | Intervention Type: DRUG; Name: Adalimumab (Humira); Assigned to Arm(s): Adalimumab (Humira) | Intervention Type: DRUG; Name: Placebo Injection; Assigned to Arm(s): Placebo Injection | Intervention Type: OTHER; Name: NB-UVB phototherapy; Assigned to Arm(s): NB-UVB phototherapy
D: Arm Label: Apremilast 30 mg plus placebo injection; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo injection | Arm Label: Etanercept 50 mg plus placebo tablet; Type: EXPERIMENTAL; Interventions: Drug: Etanercept, Drug: Placebo tablet | Arm Label: Oral placebo tablets plus SC placebo injections; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet, Drug: Placebo injection | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast 30 mg plus placebo injection | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept 50 mg plus placebo tablet | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Etanercept 50 mg plus placebo tablet, Oral placebo tablets plus SC placebo injections | Intervention Type: DRUG; Name: Placebo injection; Assigned to Arm(s): Apremilast 30 mg plus placebo injection, Oral placebo tablets plus SC placebo injections

Answer: D